Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$26.85 USD
+0.71 (2.72%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $26.86 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Travere Therapeutics, Inc.'s return on equity, or ROE, is -717.68% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that TVTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TVTX 26.85 +0.71(2.72%)
Will TVTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
What Makes Travere (TVTX) a New Strong Buy Stock
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Other News for TVTX
Is TVTX consolidating before a move? NR7 shows up after dropping 0.23%
180 Bullish Setup appears for TVTX after 4.13% move
Is TVTX consolidating before a move? NR7 shows up after sinking 3.49%
TVTX forms Shooting Star Candlestick on October 9
TVTX forms 180 Bullish Setup on October 8